Metabolic Disorder Therapeutics Market

The global metabolic disorder therapeutics market size is anticipated to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing prevalence of lifestyle disorders and growing demand for one-time therapies for metabolic disorders.

Get Free Sample Report

The breakdown of food into its essential components such as proteins, carbs or sugars, and lipids, is known as metabolism. When these regular processes are disturbed, metabolic disorders develop. A metabolic disorder develops when the body's metabolism malfunctions, resulting in either too much or too little of the vital chemicals required to be healthy. Our bodies are extremely sensitive to metabolic errors. To accomplish all of its activities, the body requires amino acids and a variety of proteins. Calcium, potassium, and salt are required by the brain to create electrical impulses, while lipids such as fats and oils are required to maintain a healthy neurological system. If some organs, such as the pancreas or the liver, stop working correctly, the body might develop a metabolic disorder. Genetics, a deficiency in a certain hormone or enzyme, eating too much of particular foods, and a variety of other variables can all contribute to these disorders. Hundreds of hereditary metabolic diseases are caused by single gene mutations. Families can carry these mutations down across generations. Gaucher's disease, glucose galactose malabsorption, hereditary hemochromatosis, Maple syrup urine disease (MSUD), and phenylketonuria are some of the most common metabolic disorders. The identification and treatment of metabolic diseases have greatly evolved. A metabolic problem can sometimes be caused by very complicated pathways. At other cases, a single little mistake in a person's DNA is entirely responsible. Scientists have been able to devise remarkable therapies for those who have been affected by these disorders as a result of these discoveries, and the rate of discovery continues to increase. Symptoms of metabolic diseases differ from person to person and by type of disease. Some metabolic diseases generate minor symptoms that may be controlled with medicine and lifestyle modifications, while others can result in severe and life-threatening symptoms including breathing difficulties, seizures, and organ failure. Some hereditary metabolic diseases may need long-term nutritional supplements and therapy, but metabolic abnormalities that develop as a result of another disease or condition usually improve after the underlying condition is treated. Untreated metabolic disorders can lead to significant complications, even death in certain circumstances.

Market Trends, Drivers, Restraints, and Opportunities

• Increasing incidence of metabolic disorders worldwide is projected to boost the market during the forecast period.
• Growing consumer awareness regarding the availability of various treatment options for metabolic disorders are expected to drive the market growth.
• Increasing demand for one-time therapies for metabolic disorders are estimated to push the market growth during the forecast period.
• Increasing diabetic and obese population around the world is anticipated to drive the market growth during the forecast period.
• Low compliance and adherence rates for metabolic disorder therapies are projected to hinder the market growth.
• Availability of alternate treatment options for metabolic disorders presents as key challenge that can impede the market growth during the forecast period.
• Increased emphasis on R&D investment for development of novel therapeutics and technological advancement are expected to offer lucrative opportunities for the market players.

Scope of the Report

The report on the global metabolic disorder therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Market Segment Insights

Diabetes segment is expected to account for a key share of the market
Based on disease the metabolic disorder therapeutics market is segmented into lysosomal storage diseases, diabetes, obesity, inherited metabolic disorders, hypercholesterolemia. lysosomal storage diseases segment is further sub segmented into gaucher’s disease, metachromatic leukodystrophy, hurler – scheie, sanfilipo a, and others. The diabetes segment is expected to account for a key share of the market during the forecast period years owing to extensive use of metabolic disease therapies such as anti-diabetic medications and injections to regulate blood sugar levels. In diabetes, it is critical to consume metabolic regulators on a regular basis. As a result of this, it is the most profitable segment.

On the other hand, the obesity segment is anticipated to expand at a rapid pace during the forecast period due to increased lifestyle changes and changing eating habits.

Drug therapy segment is expected to hold a key share of the market
Based on therapy type, the metabolic disorder therapeutics market is segmented into enzyme replacement therapy, cellular transplantation, small molecule based therapy, substrate reduction therapy, gene therapy, and drug therapy. The drug therapy segment is expected to hold a key share of the market during the forecast period owing to ease of administration and high reliability. The advent of smart medication delivery devices and smart dose management systems is also expected to boost the segment's growth.

Enzyme replacement treatment, cellular transplantation, substrate reduction treatment, small molecule-based treatment, and gene therapy, are innovative and cutting-edge therapies, making them more effective in treating metabolic disorders. However, these treatments have a number of drawbacks, including high costs and a lack of scientific validation.

Get Free Sample Report

Oral segment is expected to account constitute a key share of the market
Based on route of administration, the metabolic disorder therapeutics market is segmented into oral, parenteral, and others. The oral segment is expected to account constitute a key share of the market during the forecast period owing to its adoption in in diabetes and hypercholesterolemia treatments. Ease of use, reliability, and proven outcomes given by the oral mode of administration and increased demand for safe and smart medication delivery are the factors which are projected to drive the segment.

On the other hand, the others segment is anticipated to expand at a rapid pace during the forecast period owing to researchers strive to develop better medications and therapies that will reduce the need for lifelong diagnosis and various dose treatments. Greater emphasis on innovative treatments, such as gene therapy, has been noted in recent years as a result of diagnostic advancements. This is expected to drive the expansion of the segment in the forecast period.

North America is anticipated to dominate the market
On the basis of regions, the metabolic disorder therapeutics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market during the forecast period. The regional market growth can be attributed to Increasing prevalence of obesity and diabetes. The regional market is projected to grow further as healthcare expenditures rise and awareness of metabolic diseases increases.

On the other hand, Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to increasing economic growth in the region. The Asia Pacific market is also being driven by changing lifestyles, which have resulted in a growth in obesity, diabetes, and hypercholesterolemia illnesses, as well as rising disposable income levels.

Segments

• Lysosomal Storage Diseases
  • Gaucher’s Disease
  • Metachromatic Leukodystrophy
  • Hurler - Scheie
  • Sanfilipo A
  • Others
• Diabetes
• Obesity
• Inherited Metabolic Disorders
• Hypercholesterolemia

• Enzyme Replacement Therapy
• Cellular Transplantation
• Small Molecule Based Therapy
• Substrate Reduction Therapy
• Gene Therapy
• Drug Therapy

• Oral
• Parenteral
• Others

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

• Novo Nordisk A/S
• Sanofi S.A.
• Boehringer Ingelheim GmbH
• Eli Lilly and Company
• Merck KgaA
• Amgen, Inc.
• AstraZeneca PLC
• Actelion Pharmaceuticals Ltd.
• Shire PLC
• AbbVie, Inc.
• Biocon Ltd.
• BioMarin Pharmaceutical, Inc.
• Bristol-Myers Squibb Company
• Cipla, Inc.
• CymaBay Therapeutics, Inc.

Competitive Landscape

Key players competing in the metabolic disorder therapeutics market include/are Novo Nordisk A/S; Sanofi S.A.; Boehringer Ingelheim GmbH; Eli Lilly and Company; Merck KgaA; Amgen, Inc.; AstraZeneca PLC; Actelion Pharmaceuticals Ltd.; Shire PLC; AbbVie, Inc.; Biocon Ltd.; BioMarin Pharmaceutical, Inc.; Bristol-Myers Squibb Company; Cipla, Inc.; CymaBay Therapeutics, Inc.

Some of the key business strategies employed by companies includes mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase their market shares. For example, in 2017, Boehringer Ingelheim announced promising findings on the clinical development of Jardiance for the decrease of cardiovascular mortality in individuals with type 2 diabetes and peripheral artery disease, in partnership with Eli Lilly and Company.